Regulatory framework for biosimilar products in Brazil

In a recent news release the Brazilian National Health Monitoring Agency (ANSIVA) announced that by the end of the year, pharma firms will be required to subject so-called ‘similar’ drugs to the same bioequivalence tests as generics in order to guarantee their quality.